title: New strategies to develop new medications for lung cancer and metastasis.
abstract: With the advances in cancer and molecular biology and the rapid progress in genomics, significant progress has been made in the treatment of lung cancer in the past decade. Targeted therapies have been developed for nonsmall cell lung cancer (NSCLC), and significant improvement in survival has been achieved. There is still, however, no cure for advanced NSCLC. Resistance to initial therapy is universal, and the lethal outcome of metastatic disease still remains. Approaches to preventing metastases and overcoming resistance to therapy are necessary to ensure long-term survival of patients with advanced lung cancer.
authors.affiliation: Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA.
authors.forename: Yujie
authors.initials: Y
authors.lastname: Zhao
authors.forename: Alex A
authors.initials: AA
authors.lastname: Adjei
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D009362:Neoplasm Metastasis / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents